West Pharmaceutical Services has been on a strong run, and the share price now puts a clear spotlight on one question: Are investors paying a level that its future cash flows can reasonably support, or has the market moved ahead of what the business is likely to generate in hard dollars over time? The stock has returned 54.7% over the past year, which puts real pressure on the cash flow outlook to justify how far the valuation has moved. The business model, built around drug delivery...
Detailed price information for Zoetis Inc Cl A (ZTS-N) from The Globe and Mail including charting and trades.
Detailed price information for West Pharmaceutical Services (WST-N) from The Globe and Mail including charting and trades.
Since CNBC highlighted the stock's attractive valuation in August, shares have gained around 20%. Why we expect more upside ahead.
Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Detailed price information for West Pharmaceutical Services (WST-N) from The Globe and Mail including charting and trades.
Detailed price information for West Pharmaceutical Services (WST-N) from The Globe and Mail including charting and trades.
Detailed price information for West Pharmaceutical Services (WST-N) from The Globe and Mail including charting and trades.
Detailed price information for Timken Company (TKR-N) from The Globe and Mail including charting and trades.
CNBC traders picked WST, JPM, META and IYE; analysts raised WST and META targets, while JPM missed Q3 earnings and revenue estimates.
West Pharmaceutical's sustained premium valuation demands proven earnings and cash flow improvements. See why I rate WST stock a Sell.
West Pharmaceutical Services has seen its share price climb sharply in recent periods, and that kind of run naturally raises a question for anyone looking at the stock today: Are the cash flows the business can generate over time enough to support where the market is currently pricing West Pharmaceutical Services? The share price has gained 37.2% over the past year, which puts a lot of weight on whether the underlying cash flows can keep backing up that move. The group’s role in supplying...
West Pharma (WST) is still a buy: GLP-1 demand, HVP upgrades, and Annex 1 regulatory conversions fuel growth. Read here for a detailed analysis.
This is the newest page. Registered accounts read further back.